ATXN7L3B inhibitors are a class of chemical compounds that specifically inhibit the activity of the ATXN7L3B (ataxin-7-like 3B) protein. ATXN7L3B, closely related to ATXN7L3, is a component of multiprotein complexes involved in transcriptional regulation and chromatin modification. Like its homolog, ATXN7L3B participates in histone deubiquitination, a key process in the regulation of chromatin structure and gene expression. Histone ubiquitination and deubiquitination are critical for maintaining the proper organization of chromatin and ensuring the appropriate expression of genes. ATXN7L3B inhibitors are designed to block the protein's ability to interact with other subunits of these complexes, thereby disrupting its role in modifying chromatin and influencing transcriptional activity.
The use of ATXN7L3B inhibitors provides researchers with tools to explore how this protein specifically contributes to the regulation of gene expression and chromatin remodeling. By inhibiting ATXN7L3B, scientists can study how changes in histone deubiquitination affect the overall chromatin landscape and the downstream impacts on transcriptional regulation. These inhibitors help to delineate the unique roles of ATXN7L3B in contrast to its homologs or other components of chromatin-modifying complexes, offering deeper insights into the specificity of chromatin modification pathways. Additionally, studying ATXN7L3B inhibitors enhances the understanding of how alterations in chromatin structure can influence cellular processes such as differentiation, development, and response to environmental signals. These inhibitors are important tools for investigating the complex regulatory networks that govern chromatin dynamics and gene expression, providing a window into the intricate machinery that controls epigenetic modifications within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3K, potentially affecting downstream signaling that intersects with ATXN7L3B. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, potentially altering pathways that could intersect with ATXN7L3B activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Selectively inhibits MEK, which could impact MAPK/ERK signaling related to ATXN7L3B. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, potentially affecting MAPK/ERK signaling pathways associated with ATXN7L3B. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase, which can modulate pathways potentially connected to ATXN7L3B. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially influencing signaling pathways that could affect ATXN7L3B. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which can alter signaling pathways potentially related to ATXN7L3B. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor, potentially affecting protein turnover related to ATXN7L3B interactions. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Inhibits histone deacetylase, possibly affecting gene expression related to ATXN7L3B. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Inhibits SERCA, potentially affecting calcium signaling related to ATXN7L3B. |